Anti-CD20 treatment in primary Sjögren's syndrome

Scandinavian Journal of Immunology

Volumn 68, Issue 6, 2008, Pages 554-564

  Isaksen, K ^a   Jonsson, R ^b,c   Omdal, R ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; B CELL ACTIVATING FACTOR; CHIMERIC ANTIBODY; CLEMASTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; ETANERCEPT; HYDROCORTISONE; INFLIXIMAB; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; STEROID; VINCRISTINE;

ANKLE ARTHRITIS; ARTHRALGIA; ARTHRITIS; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; FATIGUE; FEVER; GASTROENTERITIS; HEADACHE; HEART PALPITATION; HERPES ZOSTER; HUMAN; INFLUENZA; INJECTION SITE REACTION; KIDNEY DISEASE; LABORATORY TEST; LUNG DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SJOEGREN SYNDROME; SYNOVITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS; XEROSTOMIA;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; RHEUMATOID FACTOR; SJOGREN'S SYNDROME;

EID: 55349123304     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02185.x     Document Type: Review

References (52)

1. Jonsson R, Bolstad AI, Brokstad KA, Brun JG. Sjögren's syndrome - a plethora of clinical and immunological phenotypes with a complex genetic background. Ann NY Acad Sci 2007 1108 : 433 47.
2. Manganelli P, Fietta P, Quaini F. Hematologic manifestations of primary Sjögren's syndrome. Clin Exp Rheumatol 2006 24 : 438 48.
3. Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000 29 : 20 8.
4. Sutcliffe N, Stoll T, Pyke S, Isenberg DA. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren's syndrome (SS), and primary SS. J Rheumatol 1998 25 : 63 8.
5. Tensing EK, Solovieva SA, Tervahartiala T et al. Fatigue and health profile in sicca syndrome of Sjogren's and non-Sjogren's syndrome origin. Clin Exp Rheumatol 2001 19 : 313 6.
6. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000 29 : 296 304.
7. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002 46 : 741 7.
8. Delaleu N, Jonsson R, Koller MM. Sjögren's syndrome. Eur J Oral Sci 2005 113 : 101 13.
9. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005 64 : iv55 7.
10. Schiemann B, Gommerman J L, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001 293 : 2111 4.
11. Looney R J. Will targeting B cells be the answer for Sjogren's syndrome? Arthritis Rheum 2007 56 : 1371 7.
12. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M. Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology 2008 47 : 1311 6.
13. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005 62 : 421 8.
14. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006 2 : 252 61.
15. Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004 50 : 1270 6.
16. Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004 50 : 2240 5.
17. Steinfeld SD, Tant L, Burmester GR et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006 8 : R129.
18. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435 45.
19. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996 88 (Suppl. 1 673A (Abstract).
20. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder T F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006 20 : 203.
21. Mattila M, Meri S. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages. Scand J Immunol 2008 68 : 159 68.
22. FDA approval document for Rituximab. http://www.fda.gov/cder/biologics/ review/ritugen112697-r1.pdf.
23. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 17 : 350.
24. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008 28 : 205 15.
25. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003 48 : 2146 54.
26. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with RA treated with B lymphocyte depletion. Ann Rheum Dis 2002 61 : 1 5.
27. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002 46 : 2029 33.
28. Edwards JCW, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004 30 : 393 403.
29. Papadakis KA, Rosenbloom B, Targan SR. Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology 2003 124 : 583.
30. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 : 2793 806.
31. Edvards JC, Cambridge G. Prospects for B cell targeted therapy in autoimmune diseases. Rheumatology 2005 44 : 151 6.
32. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long-term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide,doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006 65 : 1033 7.
33. Ramos-Casals M, López-Guillermo A, Brito-Zerón P, Cervera R, Font J, SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus 2004 13 : 969 71.
34. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjogren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008 67 : 1541 4.
35. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005 64 : 913 20.
36. Seror R, Sordet C, Guillevin L et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007 66 : 351 7.
37. Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007 57 : 310 7.
38. Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005 52 : 2740 50.
39. Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005 64 : 1087 8.
40. Yamout B, El-Hajj T, Barada W, Uthman I. Successful treatment of refractory neuro-Sjogren with rituximab. Lupus 2007 16 : 521 3.
41. Sève P, Gachon E, Petiot P, Stankovic K, Charhon A, Broussolle C. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome. Rheumatol Int 2007 28 : 175 7.
42. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab. Clin Rheumatol 2006 6 : 891 4.
43. Pijpe J, van Imhoff GW, Vissink A et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005 64 : 958 60.
44. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 2006 35 : 323 5.
45. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Hematology (Oxford) 2004 43 : 1309 10.
46. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003 15 : 49.
47. Sánchez-Cano D, Callejas-Rubio J, Lara-Jiménez M, López-Trascasa M, Circadi M, Ortego-Centeno N. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008 17 : 228 9.
48. Carbone J, Perez-Fernandez R, Muñoz A, Sabin P, Carreño L, Fernandez-Cruz E. Combined therapy with rituximab plus cyclophosphamide/ vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma. Clin Rev Allergy Immunol 2008 34 : 80 4.
49. Pers J-O, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007 56 : 1464 77.
50. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001 44 : 2371 5.
51. Youinou P, Mankai A, Bordron A, Berthou C. Features of rituximab-induced killing of B lymphocytes. Scand J Immunol 2008 68 : 118 9.
52. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007 34 : 430 3.